Friday 6 November 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS: −19.6%
Free cash flow: −43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%

Follow ORKA

Alert me

Market cap: $6.4B
P/E: 0.0×
Fwd P/E: —
Dividend yield: 0.00%
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Oruka Therapeutics, Inc. 8-K filed Apr 27, 2026

Period ended Apr 27, 2026 · Filed Apr 27, 2026 · accepted 8:00 AM ET · Document on sec.gov · Filing index

7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov